JP2023541191A - アミロイドーシスを治療する方法 - Google Patents

アミロイドーシスを治療する方法 Download PDF

Info

Publication number
JP2023541191A
JP2023541191A JP2023516809A JP2023516809A JP2023541191A JP 2023541191 A JP2023541191 A JP 2023541191A JP 2023516809 A JP2023516809 A JP 2023516809A JP 2023516809 A JP2023516809 A JP 2023516809A JP 2023541191 A JP2023541191 A JP 2023541191A
Authority
JP
Japan
Prior art keywords
antibody
subject
amyloidosis
dose
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023516809A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022056484A5 (https=
JP2023541191A5 (https=
Inventor
マイケル スペクター，
スーザン ビー． ソボロブ－ジェインズ，
マイケル カーサイ，
アンソニー エス． ルビニッキ，
ジェシカ ジー． ラビウォン，
Original Assignee
ケーラム バイオサイエンシーズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ケーラム バイオサイエンシーズ， インコーポレイテッド filed Critical ケーラム バイオサイエンシーズ， インコーポレイテッド
Publication of JP2023541191A publication Critical patent/JP2023541191A/ja
Publication of JPWO2022056484A5 publication Critical patent/JPWO2022056484A5/ja
Publication of JP2023541191A5 publication Critical patent/JP2023541191A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/42—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Developmental Biology & Embryology (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Cell Biology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
JP2023516809A 2020-09-14 2021-09-14 アミロイドーシスを治療する方法 Pending JP2023541191A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202063078258P 2020-09-14 2020-09-14
US63/078,258 2020-09-14
US202063116100P 2020-11-19 2020-11-19
US63/116,100 2020-11-19
US202163176015P 2021-04-16 2021-04-16
US63/176,015 2021-04-16
PCT/US2021/050316 WO2022056484A1 (en) 2020-09-14 2021-09-14 Method of treating amyloidosis

Publications (3)

Publication Number Publication Date
JP2023541191A true JP2023541191A (ja) 2023-09-28
JPWO2022056484A5 JPWO2022056484A5 (https=) 2024-09-26
JP2023541191A5 JP2023541191A5 (https=) 2024-09-26

Family

ID=80631942

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023516809A Pending JP2023541191A (ja) 2020-09-14 2021-09-14 アミロイドーシスを治療する方法

Country Status (9)

Country Link
US (1) US20230364228A1 (https=)
EP (1) EP4210753A4 (https=)
JP (1) JP2023541191A (https=)
KR (1) KR20230069161A (https=)
AU (1) AU2021339851A1 (https=)
CA (1) CA3192069A1 (https=)
IL (1) IL301047A (https=)
MX (1) MX2023002997A (https=)
WO (1) WO2022056484A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2022346750A1 (en) * 2021-09-14 2024-04-11 Caelum Biosciences, Inc. Method of treating multiple myeloma
CN120322242A (zh) * 2022-09-16 2025-07-15 联邦高等教育系统天普大学 Bag3用于治疗心脏淀粉样变性的方法和用途
WO2025194030A1 (en) 2024-03-15 2025-09-18 Alexion Pharmaceuticals, Inc. Treatment of mayo stage iiib light chain amyloidosis

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190038745A1 (en) * 2017-08-01 2019-02-07 The Trustees Of Columbia University In The City Of New York Methods and compositions for treatment of amyloid deposition diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5553963B2 (ja) * 2004-10-22 2014-07-23 アムジエン・インコーポレーテツド 組換え抗体をリフォールディングする方法
US20090028847A1 (en) * 2007-04-12 2009-01-29 Trustees Of Boston University Multiple myeloma and al amyloid immunotherapy targeting immunoglobulin light chains and uses thereof
WO2016189491A1 (en) * 2015-05-28 2016-12-01 Glaxosmithkline Intellectual Property Development Limited Novel formulation
PH12021552135A1 (en) * 2019-03-05 2022-08-31 Prothena Biosciences Ltd Methods of treating al amyloidosis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20190038745A1 (en) * 2017-08-01 2019-02-07 The Trustees Of Columbia University In The City Of New York Methods and compositions for treatment of amyloid deposition diseases

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
ACTA HAEMATOL, vol. 143, JPN6025040085, 11 June 2020 (2020-06-11), pages 373 - 380, ISSN: 0005699573 *

Also Published As

Publication number Publication date
US20230364228A1 (en) 2023-11-16
AU2021339851A1 (en) 2023-04-13
AU2021339851A8 (en) 2023-04-20
WO2022056484A1 (en) 2022-03-17
CA3192069A1 (en) 2022-03-17
EP4210753A1 (en) 2023-07-19
MX2023002997A (es) 2023-05-11
EP4210753A4 (en) 2025-01-08
KR20230069161A (ko) 2023-05-18
IL301047A (en) 2023-05-01

Similar Documents

Publication Publication Date Title
ES3041987T3 (en) Anti-fgfr2 antibodies in combination with chemotherapy agents in cancer treatment
CA3071817C (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISEASES WITH AMYLOI DEPOSITS
JP2023134701A (ja) インターロイキン１７（ｉｌ－１７）アンタゴニストを用いてｘ線陰性体軸性脊椎関節炎を治療する方法
JP2022546454A (ja) がん処置のためのｈｅｒ２、ｎｋｇ２ｄおよびｃｄ１６に結合する多重特異性結合タンパク質の医薬製剤および投薬量レジメン
JP7670713B2 (ja) 皮下投与のための抗ｃｄ３８抗体の製剤
JP2023541191A (ja) アミロイドーシスを治療する方法
US20120189618A1 (en) Superior efficacy of cd37 antibodies in cll blood samples
KR20200074993A (ko) 쇼그렌 증후군 치료에 사용하기 위한 항-cd40 항체
CA3110276A1 (en) Treatment of triple negative breast cancer with targeted tgf-b inhibition
TW202011954A (zh) 第三期nsclc之治療及與該治療相關之病理症狀之減緩
JP2021530428A (ja) 頭頸部癌の処置
CN118043072A (zh) 治疗多发性骨髓瘤的方法
US20240392028A1 (en) Method of treating multiple myeloma
TW202003577A (zh) 用於在未曾接受過治療之個體治療癌症的標靶性TGF-β抑制之給藥方案
EA050760B1 (ru) Способ лечения множественной миеломы
CN116782935A (zh) 治疗淀粉样变性的方法
WO2025218746A1 (en) Methods of treating rheumatoid arthritis
JP2019511515A (ja) 膵炎および疼痛をデス受容体アゴニストで処置するための組成物および方法
HK40109234A (zh) 用於治疗癌症的方法和组合物
TW202421194A (zh) 包含抗ｇｉｔｒ抗體之用於治療癌症的組合療法
HK40107811A (zh) 使用萨特利珠单抗治疗中枢神经系统(cns)的脱髓鞘疾病
HK40110052A (zh) 用於治疗癌症的方法和组合物

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240917

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240917

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251001

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251225

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260227

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260312